This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Singer, C. F. Articles by Schreiber, M. Search for Related Content PubMed PubMed Citation Articles by Singer, C. F. Articles by Schreiber, M.

Insulin-Like Growth Factor (IGF)-I and IGF-II Serum Concentrations in Patients with Benign and Malignant Breast Lesions

Free IGF-II Is Correlated with Breast Cancer Size

¹ Division of Special Gynecology, Department of Obstetrics and Gynecology, Ludwig-Boltzmann-Institute of Clinical Experimental Oncology, Center of Clinical and Experimental Oncology, Vienna, and ² Division of Oncology, Department of Internal Medicine, Medical University of Vienna, Vienna, Austria

ABSTRACT

Purpose: Insulin-like growth factors (IGFs) are potent mitogens for breast cancer cells in vitro, and elevated IGF-I serum levels are a risk factor for breast malignancies. This study evaluated IGF-I and IGF-II serum levels in healthy women and in patients with benign and malignant breast lesions and correlated them with tumor size.

Experimental Design: Serum levels of the total and unbound fractions of IGF-I and IGF-II were analyzed in 65 patients with benign and malignant breast lesions and in 38 women without breast disease. ELISAs were used to detect serum IGF levels, with (total IGF) or without (free IGF) prior acid-ethanol extraction.

Results: Total IGF-I serum concentrations were lower in healthy women than in breast cancer patients (P < 0.001) or patients with benign breast lesions (P = 0.010), but no differences were observed in free IGF-I levels. Conversely, healthy women had higher serum levels of free IGF-II than women with breast lesions (P = 0.003), and the free/total IGF-II ratio was significantly reduced in patients with breast disease (P = 0.001). Although IGF-I or IGF-II serum concentrations of breast cancer patients were similar to those of patients with benign lesions, the size of a malignant tumor was correlated to the ratio free/total IGF-II (P = 0.002).

Conclusions: Malignant breast tumors cannot be distinguished from benign breast lesions by systemic IGF serum levels. However, women with breast lesions have decreased IGF-II concentrations, and free IGF-II levels are clearly correlated to the size of a breast cancer, indicating an involvement in tumor growth.

INTRODUCTION

The insulin-like growth factors (IGFs) I and II are among the most potent stimulators of cell proliferation in humans (1) . Expressed in most organs, they are systemic hormones, as well as locally acting growth factors with paracrine and autocrine functions (2) . Their bioavailability is regulated by a family of at least six IGF binding proteins (IGFBPs), which can bind and inactivate IGFs but also potentiate their activity under specific conditions (3 , 4) . In serum, the majority of systemic IGF-I and IGF-II is bound to IGFBP3 in a ternary complex with an acid-labile subunit, which serves as a physiological transporter and restricts the bioavailability of IGFs (5) . Proteolytic cleavage of IGFBPs by cathepsins and matrix metalloproteinases results in decreased affinity and releases IGFs out of the binding complex (6) . There is now substantial evidence that IGFs are involved in malignant transformation and tumor cell growth. The association between serum IGF-I and breast cancer has been postulated for some time. Recent control-matched epidemiological studies have demonstrated that high IGF-I and low IGFBP3 levels are associated with an increased risk of breast cancer in premenopausal women (7 , 8) . Both IGF-I and IGF-II are released by tumor fibroblasts and by some breast cancer cell lines, and there seems to be a shift from fibroblastic IGF-I to IGF-II expression in the immediate vicinity of invasive tumor cells as compared with surrounding breast stroma (9 , 10) . Furthermore, in vitro and in vivo studies have suggested that the overexpression of IGF-II in MCF-7 tumor cells results in the conversion to a more malignant phenotype and an increased efficiency of tumor formation in nude mice (11) . Conversely, tumor growth in IGF-I-deficient mice is reduced relative to control animals (12) . Several studies have demonstrated elevated IGF-I and reduced IGFBP3 tissue and plasma concentrations in breast cancer patients, and some have even suggested their potential use as prognostic factors (13, 14, 15) .

Although a lot of clinical data regarding the role of IGF-I and IGFBPs in human malignancies have emerged over the last years, little is still known about the role of IGF-II in malignant breast tumors. We have therefore investigated IGF-I and IGF-II serum concentrations in women with benign and malignant breast lesions and compared them to age-matched healthy controls. Because in human serum > 95% of IGFs in the circulation are bound to IGFBPs and thus biologically inactive, we measured free IGF-I and IGF-II concentrations, as well as total (= protein bound + free) IGF concentrations after acid-ethanol extraction from binding proteins. The ratio-free IGF/total IGF was used to describe the fraction of bioavailable IGF.

PATIENTS AND METHODS

Subjects and Serum Collection.
Serum samples were collected from 65 women undergoing surgery for suspicious breast lesions and from 38 women without evidence of benign or malignant breast disease (Table 1) . None of the patients had undergone cancer treatment previously. All patients had given written informed consent before blood sample collection. The use of the collected material for serum analyses had been approved by the Institutional Review Board of the Medical School of the University of Vienna. The control group consisted of age-matched women who were either consenting healthy staff nurses or women undergoing routine preoperative blood analysis for minor surgery for nongynecological reasons (Table 1) . All patients and control subjects were of Caucasian race. None of the women in the control group had a history of breast cancer or any other breast disease. Controls were within a range of 1–2 years of age with the breast cancer group. To avoid any significant influence of the nutritional status on the pattern of circulating IGF levels, all samples were obtained between 9 a.m. and 11 a.m. and in fasting condition on the day of admission to the hospital. After 2 h of incubation at room temperature for clotting, serum was separated by centrifugation at 2000 x g for 30 min and frozen at –80°C until analysis. The breast cancer group (n = 42) was comprised of ductal (n = 34), lobular (n = 7), and tubular (n = 1) carcinomas, and tumor sizes ranged from pT1 (n = 22), pT2 (n = 13), and pT3 (n = 2) to pT4 (n = 5). Benign breast lesions (n = 23) were either fibroadenomas (n = 9) or fibrous cystic mastopathy with or without calcifications (n = 14).

Free IGF-II and total IGF-II serum concentrations were determined by using the Active-free IGF2 ELISA and the Active IGF2 ELISA from Diagnostic Systems Laboratory. After a preassay acid-ethanol extraction step to liberate protein-bound IGF-II in the Active IGF2 ELISA, IGF-II was measured in an enzymatically amplified two-step sandwich-type immunoassay as described for IGF-I.

Statistical Analyses.
All statistical analyses were performed with the SPSS 10.0.1 software (SPSS, Inc., Chicago, IL). Possible differences in total and free IGF concentrations between populations were analyzed using the Mann-Whitney U test. Correlations between tumor diameter and IGF serum concentrations were evaluated using the Spearman rank correlation analysis. Multiple linear regression analysis was performed to analyze the influence of single parameters on tumor size after neutralization of confounding variables. Because logistic regression analysis relies less on distributional assumptions than linear regression analysis, correlations between the ratio variables free IGF-I/total IGF-I and free IGF-II/total IGF-II and tumor size were investigated by a multiple logistic regression model.

RESULTS

IGF Serum Concentrations in Breast Tumor Patients.
Serum concentrations of total IGF-I, free IGF-I, total IGF-II, and free IGF-II were measured by sandwich-type immunoassays in 38 healthy women, in 42 women suffering from breast cancer, and in 23 women with benign breast disease. Results of both free (i.e., unbound fraction) and total (i.e., unbound plus protein-bound/inactive fraction) IGF concentrations, as well as the ratios free IGF/total IGF, are depicted in Fig. 1 .

View larger version (25K): [in this window] [in a new window] [Download PPT slide]   Fig. 1. Box blot presentation of total and free IGF-I and IGF-II serum concentrations in healthy women (healthy), in patients with benign breast lesions (benign), and in breast cancer patients (malignant; Ref. 38 ).

Consequently, when compared with age-matched healthy individuals, lower ratios of free IGF-I/total IGF-I and of free IGF-II/total IGF-II were both characteristic of malignant disease (free IGF-I/total IGF-I: P = 0.007; free IGF-II/IGF-II: P = 0.009) and of benign breast tumors (free IGF-I/IGF-I: P = 0.019; free IGF-II/IGF-II: P = 0.002). No significant differences in any of the IGF serum levels analyzed were found when samples of patients with malignant and benign breast tumors were compared (data not shown). Furthermore, a comparison between IGF concentrations of women who either had no breast tumor at all or who had benign breast disease (nonmalignant) and of women with invasive breast cancer (malignant) yielded no significant difference with the exception of total IGF-I (226.9 versus 175.9 ng/ml; P = 0.011).

Correlation between IGF Serum Concentrations and Tumor Size.
In Table 3 , Spearman’s analysis was used to investigate possible correlations between free and total IGF-I or IGF-II to the size of 41 malignant tumors as assessed by histopathological analysis. One patient with a pT1 tumor was omitted from this analysis because the exact tumor size was not known. Although the parameters free IGF-I, free IGF-I/total IGF-I, and total IGF-II were not correlated to tumor diameter, total IGF-I was found to be negatively correlated to breast cancer size (r = –0.317, P = 0.044). Interestingly, free IGF-II was positively correlated to tumor size (r = 0.350, P = 0.025). The ratio-free IGF-II/total IGF-II was even very significantly correlated to tumor size (r = 0.469, P = 0.002).

DISCUSSION

IGF-I and IGF-II are among the most potent growth stimulatory factors known to date, and both growth factors have been associated with malignant breast disease (17) . Their biological activity is regulated by a number of IGFBPs, which are believed to bind and inactivate IGFs but which can also act as modulators of tumorigenesis through IGF-independent mechanisms (18) . These IGFBPs are thought to exert both positive and negative regulatory effects on IGF activity. On the one hand, binding of IGFs to their binding proteins protects them from degradation, thus increasing the total amount of IGFs in the circulation; on the other hand, IGFBP-bound IGFs cannot simultaneously bind to their cognate receptor, which constitutes the major negative regulatory role of IGFBPs on the bioavailability and biological activity of IGF-I and IGF-II (19) . Furthermore, free IGF-I was demonstrated to cross the endothelial cell barrier of blood vessels more readily than IGFBP-bound IGF-I (20) . These complex, both positive and negative, regulatory effects of IGFBPs on the activity of IGF-I and IGF-II are reflected by the complex relationship between serum levels of IGFBP3, the major IGFBP in the blood, and breast cancer risk. Although most studies have found a correlation between low serum levels of IGFBP3 and increased breast cancer risk, others have found the opposite (7 , 19 , 21 , 22) . Presumably, a key role in development of breast cancer is linked not only to the absolute levels of IGFBPs but rather to an imbalance in the concentration of IGFs and their binding proteins (21) .

Recently, there has been a lot of interest in the measurement of free IGFs in the plasma, which are considered to be the biologically available and thus active fraction. Although the existence of a truly free IGF plasma compartment is controversially discussed, pharmacokinetic studies indicate that a small percentage of IGFs is not associated with IGFBPs (23) . It has been demonstrated that exogenously administered IGFs almost immediately associate with low molecular weight IGFBPs, then quickly move into a high molecular weight ternary complex together with a liver-derived glycoprotein known as the acid-labile subunit. Ternary complexes do not appear to be easily dissociated and do not re-equilibrate with exogenously added IGF or IGFBP3 to a significant degree. Several investigators have therefore assayed specific IGFBPs to assess the protein-bound and presumably biologically inactive IGF fraction. Because IGFBP3 is considered the principal binding protein in the circulation, it was most commonly used as a surrogate parameter for protein-bound IGFs (24) . Women with relatively high levels of total IGF and comparably low levels of IGFBP3 were found to be at higher risk for breast cancer than women with the same levels of IGF-I but unselected for IGFBP3 (7) . Although this correction for IGFBP3 did not allow to directly quantify the levels of free IGF-I, it is reasonable to assume that woman with low serum levels of IGFBP3 have a higher average fraction of free IGF-I, indicating that not only the levels of total IGF but also those of free IGF play a crucial role in breast cancer risk. However, in human serum, IGFBP3 accounts for only 75% of protein-bound IGFs, and recently, it has been reported that IGFBP5 can form ternary circulating complexes with IGF-I and acid-labile subunit as well (25) . Furthermore, a family of IGF-specific low-affinity IGFBP-related proteins have been identified (IGFBP-related proteins 1–4). Its members possess the capacity to act on target cells independently of IGFs and can bind IGF, although to a much lesser extent than the classical IGFBPs (26) .

To further address this questions, we aimed at a direct quantification of the levels of both total and free IGF-I and IGF-II in a side-by-side comparison. Accordingly, we have used a modified acid-ethanol extraction/precipitation method to liberate all protein-bound IGF for measurement of the total amount of IGF-I and IGF-II in serum samples. This method has an excellent correlation with acid-column chromatography, which is considered the gold standard for separating IGFs from their respective binding proteins (27) . The free IGF/total IGF ratio was then used to describe the nonprotein-bound IGF fraction of the total (i.e., nonprotein-bound and protein-bound) IGF levels. Using this technique, we found total IGF-I levels to be elevated in both patients with benign and malignant breast lesions when compared with age-matched healthy controls (P < 0.001, Fig. 1 and Table 2 ). These findings are consistent with previous studies of elevated IGF-I levels in patients with breast cancer. Unfortunately, these studies did not include benign breast lesions (19 , 21 , 22 , 28) . Indeed, a comparison of both total and free IGF-I levels in benign and malignant lesions did not yield any statistically significant difference, demonstrating that malignant tumors cannot be identified by systemic IGF-I concentrations. Although our observations appear to be somewhat contrasting to epidemiological studies that found serum IGF-I to be correlated with an increased risk for breast cancer, they are well in line with findings by Ng et al. (29) , who did not find significant differences in IGF-I serum levels between actual breast cancer patients and women suffering from benign breast lesions in a case-control study, and with findings by Holdaway et al. (30) , who also did not observe differences in serum IGF-I levels between healthy individuals and women having benign or malignant breast lesions in RIAs.

Even more interestingly, no difference was found in free and presumably bioactive IGF-I serum concentrations between healthy women and patients with benign or malignant breast disease (Fig. 1 and Table 2 ). This result appears somewhat counterintuitive if one assumes that free IGF-I is the biologically active form; however, other studies have also shown that total IGF-I was more strongly associated with breast cancer risk than free IGF-I, in agreement with evidence that high rather than low levels of IGFBP3 are associated with breast cancer (21 , 22) . Muti et al. (21) proposed that there might be a threshold effect and that free IGF-I may exert a permissive effect toward breast cancer development only if its levels are high enough to exceed the rapid degradation process to which free but not IGFBP-bound IGF-I is subjected in blood serum.

Total IGF-II did not appear to be associated with benign or malignant breast lesions, in agreement with previous studies (19 , 22) . However, we found that free IGF-II serum levels were significantly lower in breast tumor patients than in healthy controls (Fig. 1 and Table 2 ). Consequently, the free IGF-II/total IGF-II ratio was decreased in women with breast lesions (median values of 0.030 versus 0.025, P < 0.001; Table 2 ). It appears paradoxical that in breast tumor patients serum concentrations of a mitogenic growth factor are lower than in healthy women; however, two possibilities can be discussed: (a) breast lesions contain larger numbers of IGF-II/mannose 6 phosphate receptor than normal tissues and can thus bind and internalize more free IGF-II, thereby lowering free IGF-II serum concentrations (31) . However, as malignant tumors grow and become more aggressive, they usually spread into local lymph nodes—an advanced state that has already been associated with a decreased ability to produce IGF-II/mannose 6 phosphate receptor (32) . A decrease of IGF-II binding sites in larger tumors might well serve as an explanation why, despite an overall reduction of total IGF-II, levels of free IGF-II actually increase significantly (Table 4) . (b) Alternatively, tumor cells or their stromal environment could respond to tumor-derived cytokines with an overcompensating expression of IGF-II-neutralizing proteins such as IGFBPs or soluble IGF-II receptors (33 , 34) . Considering that total IGF-II levels are indeed similar in women with and without breast tumors (Table 2) , increased binding of IGF-II by IGFBPs or soluble IGF-II receptors could decrease the fraction of free IGF-II.

The observation that in breast cancer patients tumor size is significantly correlated to free IGF-II levels appears contradictory to the increased levels of free IGF-II in healthy women (Table 2) . It is, however, in analogy to findings by Helle et al. (35 , 36) , who detected increased IGFBP3 proteolysis most frequently in patients harboring large tumors and metastatic disease and who saw an inverse correlation between serum levels of IGF-I/II and IGFBP3 proteolysis. An increased tumor diameter would thus result in an elevation of the fraction of non-IGFBP3-bound IGFs and could eventually cause the elevated serum levels of free IGF-II that we observed.

It also fits well our previous findings that breast cancer cells can influence the IGF expression pattern in neighboring stromal fibroblasts: fibroblasts derived from a malignant tumor express mostly IGF-II mRNA and protein, whereas fibroblasts from adjacent normal and unaffected tissue of the same patients tend to express more often IGF-I than IGF-II mRNA. Furthermore, in coculture with MCF-7 breast cancer cells, breast fibroblasts increased IGF-II mRNA expression most likely through the clonal selection of IGF-II-expressing subpopulations (10) . The intratumoral shift from IGF-I to IGF-II could thus find its reflection in systemic IGF levels and help to explain why free IGF-II concentrations and the free IGF-II/total IGF-II ratio are directly and total IGF-1 concentrations are indirectly correlated to the size of a malignant breast tumor (Table 3) . The relevance of our findings in vivo is supported by a recently published article by Holdaway et al. (37) , who found that in breast cancer patients, tumorectomy leads to a transient but significant fall in IGF-II but not in IGF-I and IGFBP3 serum concentrations. Even more interestingly, the fall in IGF-II is significantly related to the size of the removed tumor, thus indicating a significant intratumoral IGF-II production (37) .

Taken together, we have shown for the first time that in breast cancer patients, free IGF-II serum concentrations and the free IGF-II/total IGF-II ratio are well correlated with tumor size, thus suggesting a role of this growth factor in the growth control of malignant tumors. Furthermore, we have demonstrated that total IGF-I serum concentrations are increased and that free IGF-II serum concentrations are decreased in women with breast tumors. However, benign and malignant tumors cannot be distinguished by their systemic IGF concentrations, in disagreement with previous studies, which have implied that IGF-I expression is somewhat specific for malignant tumor growth (13 , 28) .

ACKNOWLEDGMENTS

We thank Ernst Ruecklinger for help with statistical analysis.

FOOTNOTES

Grant support: The Ludwig Boltzmann Institute of Clinical Experimental Oncology, the Kommission Onkologie der Medizinischen Fakultaet der Universitaet Wien, the Austrian Central Bank (OeNB), the Jubilaeumsfonds der Stadt Wien für die Oesterreichische Akademie der Wissenschaften, and the Medizinisch-Wissenschaftlicher Fonds des Buergermeisters der Bundeshauptstadt Wien.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: C. F. Singer and M. Mogg contributed equally to this work.

Requests for reprints: Martin Schreiber, Medical University of Vienna, Department of Obstetrics and Gynecology, Waehringer Guertel 18-20, A-1090 Vienna, Austria. Phone: 43-1-40400-2738; Fax: 43-1-40400-7842; E-mail: martin.schreiber{at}akh-wien.ac.at

Received 8/26/03; revised 2/17/04; accepted 3/10/04.

REFERENCES

1. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst (Bethesda), 92: 1472-89, 2000.[Abstract/Free Full Text]
2. Ellis MJ, Jenkins S, Hanfelt J, et al Insulin-like growth factors in human breast cancer. Breast Cancer Res Treat, 52: 175-84, 1998.[CrossRef][Medline]
3. Yee D, Favoni RE, Lippman ME, Powell DR. Identification of insulin-like growth factor binding proteins in breast cancer cells. Breast Cancer Res Treat, 18: 3-10, 1991.[CrossRef][Medline]
4. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev, 16: 3-34, 1995.[Abstract/Free Full Text]
5. Baxter RC, Martin JL, Beniac VA. High molecular weight insulin-like growth factor binding protein complex. Purification and properties of the acid-labile subunit from human serum. J Biol Chem, 264: 11843-8, 1989.[Abstract/Free Full Text]
6. Fowlkes JL, Enghild JJ, Suzuki K, Nagase H. Matrix metalloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures. J Biol Chem, 269: 25742-6, 1994.[Abstract/Free Full Text]
7. Hankinson SE, Willett WC, Colditz GA, et al Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet, 351: 1393-6, 1998.[CrossRef][Medline]
8. Toniolo P, Bruning PF, Akhmedkhanov A, et al Serum insulin-like growth factor-I and breast cancer. Int J Cancer, 88: 828-32, 2000.[CrossRef][Medline]
9. Quinn KA, Treston AM, Unsworth EJ, et al Insulin-like growth factor expression in human cancer cell lines. J Biol Chem, 271: 11477-83, 1996.[Abstract/Free Full Text]
10. Singer C, Rasmussen A, Smith HS, Lippman ME, Lynch HT, Cullen KJ. Malignant breast epithelium selects for insulin-like growth factor II expression in breast stroma: evidence for paracrine function. Cancer Res, 55: 2448-54, 1995.[Abstract/Free Full Text]
11. Cullen KJ, Lippman ME, Chow D, Hill S, Rosen N, Zwiebel JA. Insulin-like growth factor-II overexpression in MCF-7 cells induces phenotypic changes associated with malignant progression. Mol Endocrinol, 6: 91-100, 1992.[Abstract/Free Full Text]
12. Yang XF, Beamer WG, Huynh H, Pollak M. Reduced growth of human breast cancer xenografts in hosts homozygous for the lit mutation. Cancer Res, 56: 1509-11, 1996.[Abstract/Free Full Text]
13. Peyrat JP, Bonneterre J, Hecquet B, et al Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur J Cancer, 29A: 492-7, 1993.
14. Rocha RL, Hilsenbeck SG, Jackson JG, et al Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival. Clin Cancer Res, 3: 103-9, 1997.[Abstract]
15. Bruning PF, Van Doorn J, Bonfrer JM, et al Insulin-like growth-factor-binding protein 3 is decreased in early-stage operable pre-menopausal breast cancer. Int J Cancer, 62: 266-70, 1995.[Medline]
16. Pollak M, Costantino J, Polychronakos C, et al Effect of tamoxifen on serum insulin-like growth factor I levels in stage I breast cancer patients. J Natl Cancer Inst (Bethesda), 82: 1693-7, 1990.[Abstract/Free Full Text]
17. Rosen N, Yee D, Lippman ME, Paik S, Cullen KJ. Insulin-like growth factors in human breast cancer. Breast Cancer Res Treat, 18 (Suppl. 1): S55-62, 1991.
18. Salahifar H, Baxter RC, Martin JL. Insulin-like growth factor binding protein (IGFBP)-3 protease activity secreted by MCF-7 breast cancer cells: inhibition by IGFs does not require IGF-IGFBP interaction. Endocrinology, 138: 1683-90, 1997.[Abstract/Free Full Text]
19. Li BD, Khosravi MJ, Berkel HJ, et al Free insulin-like growth factor-I and breast cancer risk. Int J Cancer, 91: 736-9, 2001.[CrossRef][Medline]
20. Bastian SE, Walton PE, Ballard FJ, Belford DA. Transport of IGF-I across epithelial cell monolayers. J Endocrinol, 162: 361-9, 1999.[Abstract]
21. Muti P, Quattrin T, Grant BJ, et al Fasting glucose is a risk factor for breast cancer: a prospective study. Cancer Epidemiol Biomark Prev, 11: 1361-8, 2002.[Abstract/Free Full Text]
22. Yu H, Jin F, Shu XO, et al Insulin-like growth factors and breast cancer risk in Chinese women. Cancer Epidemiol Biomark Prev, 11: 705-12, 2002.[Abstract/Free Full Text]
23. Rajaram S, Baylink DJ, Mohan S. Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev, 18: 801-31, 1997.[Abstract/Free Full Text]
24. Holman SR, Baxter RC. Insulin-like growth factor binding protein-3: factors affecting binary and ternary complex formation. Growth Regul, 6: 42-7, 1996.[Medline]
25. Twigg SM, Baxter RC. Insulin-like growth factor (IGF)-binding protein 5 forms an alternative ternary complex with IGFs and the acid-labile subunit. J Biol Chem, 273: 6074-9, 1998.[Abstract/Free Full Text]
26. Oh Y. IGFBPs and neoplastic models. New concepts for roles of IGFBPs in regulation of cancer cell growth. Endocrine, 7: 111-3, 1997.[Medline]
27. Powell DR, Rosenfeld RG, Baker BK, Liu F, Hintz RL. Serum somatomedin levels in adults with chronic renal failure: the importance of measuring insulin-like growth factor I (IGF-I) and IGF-II in acid-chromatographed uremic serum. J Clin Endocrinol Metab, 63: 1186-92, 1986.[Abstract/Free Full Text]
28. Favoni RE, de Cupis A, Perrotta A, et al Insulin-like growth factor-I (IGF-I) and IGF-binding proteins blood serum levels in women with early- and late-stage breast cancer: mutual relationship and possible correlations with patients’ hormonal status. J Cancer Res Clin Oncol, 121: 674-82, 1995.[CrossRef][Medline]
29. Ng EH, Ji CY, Tan PH, Lin V, Soo KC, Lee KO. Altered serum levels of insulin-like growth factor binding proteins in breast cancer patients. Ann Surg Oncol, 5: 194-201, 1998.[Abstract]
30. Holdaway IM, Mason BH, Lethaby AE, et al Serum levels of insulin-like growth factor binding protein-3 in benign and malignant breast disease. Aust N Z J Surg, 69: 495-500, 1999.[CrossRef][Medline]
31. Ellis MJ, Leav BA, Yang Z, et al Affinity for the insulin-like growth factor-II (IGF-II) receptor inhibits autocrine IGF-II activity in MCF-7 breast cancer cells. Mol Endocrinol, 10: 286-97, 1996.[Abstract/Free Full Text]
32. Zhao Y, Escot C, Maudelonde T, Puech C, Rouanet P, Rochefort H. Correlation between mannose-6-phosphate/IGFII receptor and cathepsin D RNA levels by in situ hybridization in benign and malignant mammary tumors. Cancer Res, 53: 2901-5, 1993.[Abstract/Free Full Text]
33. Rocha RL, Hilsenbeck SG, Jackson JG, Lee AV, Figueroa JA, Yee D. Correlation of insulin-like growth factor-binding protein-3 messenger RNA with protein expression in primary breast cancer tissues: detection of higher levels in tumors with poor prognostic features. J Natl Cancer Inst (Bethesda), 88: 601-6, 1996.[Abstract/Free Full Text]
34. Confort C, Rochefort H, Vignon F. Insulin-like growth factors (IGFs) stimulate the release of alpha 1-antichymotrypsin and soluble IGF-II/mannose 6-phosphate receptor from MCF7 breast cancer cells. Endocrinology, 136: 3759-66, 1995.[Abstract]
35. Helle SI, Geisler S, Aas T, Paulsen T, Holly JM, Lonning PE. Plasma insulin-like growth factor binding protein-3 proteolysis is increased in primary breast cancer. Br J Cancer, 85: 74-7, 2001.[CrossRef][Medline]
36. Helle SI, Geisler J, Anker GB, Leirvaag B, Holly JM, Lonning PE. Alterations in the insulin-like growth factor system during treatment with diethylstilboestrol in patients with metastatic breast cancer. Br J Cancer, 85: 147-51, 2001.[CrossRef][Medline]
37. Holdaway IM, Lethaby AE, Mason BH, et al Effect of breast surgery on serum levels of insulin-like growth factors (IGF-I, IGF-II, and IGF binding protein-3) in women with benign and malignant breast lesions. Ann Surg Oncol, 8: 25-31, 2001.[Abstract/Free Full Text]
38. Williamson DF, Parker RA, Kendrick JS. The box plot: a simple visual method to interpret data. Ann Intern Med, 110: 916-21, 1989.

This article has been cited by other articles:

				J. VRZALOVA, M. PRAZAKOVA, Z. NOVOTNY, O. TOPOLCAN, M. CASOVA, and L. HOLUBEC JR. Test of Ovarian Cancer Multiplex xMAP Technology Panel Anticancer Res, February 1, 2009; 29(2): 573 - 576. [Abstract] [Full Text] [PDF]

				G Hudelist, T Wagner, M Rosner, A Fink-Retter, D Gschwantler-Kaulich, K Czerwenka, R Kroiss, M Tea, K Pischinger, W J Kostler, et al. Intratumoral IGF-I protein expression is selectively upregulated in breast cancer patients with BRCA1/2 mutations Endocr. Relat. Cancer, December 1, 2007; 14(4): 1053 - 1062. [Abstract] [Full Text] [PDF]

				Y. Mitsui, S. Mochizuki, T. Kodama, M. Shimoda, T. Ohtsuka, T. Shiomi, M. Chijiiwa, T. Ikeda, M. Kitajima, and Y. Okada ADAM28 Is Overexpressed in Human Breast Carcinomas: Implications for Carcinoma Cell Proliferation through Cleavage of Insulin-like Growth Factor Binding Protein-3. Cancer Res., October 15, 2006; 66(20): 9913 - 9920. [Abstract] [Full Text] [PDF]

				G. Mor, I. Visintin, Y. Lai, H. Zhao, P. Schwartz, T. Rutherford, L. Yue, P. Bray-Ward, and D. C. Ward Serum protein markers for early detection of ovarian cancer PNAS, May 24, 2005; 102(21): 7677 - 7682. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Singer, C. F. Articles by Schreiber, M. Search for Related Content PubMed PubMed Citation Articles by Singer, C. F. Articles by Schreiber, M.